MedPath

coenzyme Q10 and L carnitine in Benign prismatic hyperplasia

Phase 3
Recruiting
Conditions
Condition 1: Benign prostatic hyperplasia. Condition 2: Lower urinary tract symptoms.
Registration Number
IRCT20200623047893N1
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
50
Inclusion Criteria

50-75 years old
IPSS=8-19
Prostate volume 40-60 cc

Exclusion Criteria

urinary tract infections
severe liver disease
diabetes
recent treatment with 5 alpha reductase
recent treatment with phototherapy
treatment with antiandrogens and antidepressants
neurological bladder
bladder cancer
prostate cancer
Take atorvastatin
blood pressure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in prostate volume. Timepoint: The beginning the study and the end of study. Method of measurement: Sonography.
Secondary Outcome Measures
NameTimeMethod
IIEF. Timepoint: The beginning and the end of study. Method of measurement: Questionnaire.
© Copyright 2025. All Rights Reserved by MedPath